Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 1/20 | 0.58 |
| ▸ | BTK | Q06187 | 1/20 | 0.58 |
| ▸ | KDM4D | Q6B0I6 | 2/20 | 0.55 |
| ▸ | RET | P07949 | 7/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.52 |
| ▸ | CTSK | P43235 | 2/20 | 0.52 |
| ▸ | SYK | P43405 | 1/20 | 0.51 |
| ▸ | CKS1B | P61024 | 1/20 | 0.50 |
| ▸ | SKP1 | P63208 | 1/20 | 0.50 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.50 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.50 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.49 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21522253 | 0.94 | JAK3 (0.66) | JAK3BTKKDM4DRETMAP4K4 | |
| SCHEMBL7078845 | 0.94 | RET (0.57) | JAK3BTKKDM4DRETCTSK | |
| SCHEMBL26582234 | 0.91 | GRM4 (0.52) | JAK3BTKKDM4DRETMAP4K4 | |
| SCHEMBL30546199 | 0.91 | GRM4 (0.52) | JAK3BTKKDM4DRETMAP4K4 | |
| SCHEMBL596151 | 0.85 | MAP4K4 (0.58) | JAK3BTKRETMAP4K4CTSK | |
| SCHEMBL594137 | 0.85 | MAP4K4 (0.58) | JAK3BTKRETMAP4K4CTSK | |
| SCHEMBL529863 | 0.85 | MAP4K4 (0.58) | JAK3BTKRETMAP4K4CTSK | |
| SCHEMBL20051576 | 0.84 | USP30 (0.58) | JAK3BTKKDM4DRETMAP4K4 | |
| SCHEMBL1350284 | 0.84 | JAK3 (0.56) | JAK3BTKRETMAP4K4CTSK | |
| SCHEMBL389069 | 0.84 | SYK (0.53) | JAK3BTKRETMAP4K4CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS, INC. | 2025-01-30 | — | — | US | disclosed |
| EP-4234551-A2 | PYRIDAZINONES AS PARP7 INHIBITORS | Ribon Therapeutics Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230192664-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2023-06-22 | — | — | US | disclosed |
| EP-3788040-B1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS INC (US) | 2023-04-12 | — | — | EP | disclosed |
| US-11566020-B1 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-11014913-B2 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| EP-3788040-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | Ribon Therapeutics Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| CN-112424188-A | Pyridazinones as PARP7 inhibitors | 里邦医疗公司 | 2021-02-26 | — | — | CN | disclosed |
| US-20210024502-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2021-01-28 | — | — | US | disclosed |
| US-10550105-B2 | Pyridazinones as PARP7 inhibitors | Ribon Therapeutics Inc. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190330194-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2019-10-31 | — | — | US | disclosed |
| US-7868014-B2 | 1-(hetero)aryl-3-amino-pyrrolidine derivatives for use as mGluR3 antagonists | ELI LILLY AND COMPANY (US) | 2011-01-11 | — | — | US | disclosed |
| EP-1805165-B1 | 1-(HETERO)ARYL-3-AMINO-PYRROLIDINE DERIVATIVES FOR USE AS MGLUR3 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2009-12-16 | — | — | EP | disclosed |
| US-20080300266-A1 | 1-(Hetero)Aryl-3-Amino-Pyrrolidine Derivatives for Use as Mglur3 Antagonists | ELI LILLY AND COMPANY (US) | 2008-12-04 | — | — | US | disclosed |
| EP-1805165-A1 | 1-(HETERO)ARYL-3-AMINO-PYROLLIDINE DERIVATIVES FOR USE AS MGLUR3 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006044454-A1 | 1-(HETERO)ARYL-3-AMINO-PYROLLIDINE DERIVATIVES FOR USE AS MGLUR3 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024502-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | JAK3 2263/4885BTK 2308/4885KDM4D 1205/4885 |
| US-10550105-B2 | Pyridazinones as PARP7 inhibitors | PARP2, PARP1, PARP4 | JAK3 2263/4885BTK 2308/4885KDM4D 1205/4885 |
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | JAK3 2263/4885BTK 2308/4885KDM4D 1205/4885 |
| US-20190330194-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | JAK3 2263/4885BTK 2308/4885KDM4D 1205/4885 |
| US-11014913-B2 | Pyridazinones as PARP7 inhibitors | PARP2, PARP1, PARP4 | JAK3 2263/4885BTK 2308/4885KDM4D 1205/4885 |
| US-11566020-B1 | Pyridazinones as PARP7 inhibitors | PARP2, PARP1, PARP4 | JAK3 2263/4885BTK 2308/4885KDM4D 1205/4885 |
| US-20080300266-A1 | 1-(Hetero)Aryl-3-Amino-Pyrrolidine Derivatives for Use as Mglur3 Antagonists | GRM3, GRM1, GRIA3 | JAK3 545/4885BTK 4594/4885KDM4D 2845/4885 |
| US-20230192664-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | JAK3 2263/4885BTK 2308/4885KDM4D 1205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.